Generally, the definition of relapse in multiple myeloma is the reappearance of signs and symptoms of a disease after a period of improvement. Patients with relapsed multiple myeloma are those who have been treated and then developed verifiable signs of the disease that have been precisely defined by the International Myeloma Working Group (IMWG). The IMWG response criteria are used to determine patients' responses during treatment in clinical trials and are necessarily very precise

The International Myeloma Working Group consensus criteria for response and minimal residual disease assessment, published in The Lancet Oncology in August 2016, states that clinical relapse requires one or more of the following criteria that are direct indicators of increasing disease and/or end-organ dysfunction (CRAB features):

  • Definite increase in the size of existing plasmacytomas or bone lesions.
  • Hypercalcemia (> 11 mg/dL).
  • Decrease in hemoglobin of ≥ 2 g/dL not related to therapy or other non-myeloma-related conditions.
  • Rise in serum creatinine by 2 mg/dL or more from the start of the therapy and attributable to myeloma.
  • Hyperviscosity related to serum protein.
  • Increase of 25% from the lowest confirmed response value in one or more of the following criteria:
    • Serum M-protein (the increase must be at least 0.5 g/dL).
    • Urine M-protein (the increase must be at least 200 mg/24 hours).
    • If no serum or urine M-protein can be measured, the difference between the involved (abnormal, or monoclonal) and uninvolved (normal or polyclonal) free light chain levels (the increase must be >10 mg/dL).

The following may be signs that multiple myeloma is relapsing based not upon CRAB criteria, but upon biological markers.

No patient should be treated solely "by the numbers," however. Your disease history and your doctor's experience and judgment must guide the decision to change or re-start treatment. Multiple myeloma is different in every patient, and each patient must be evaluated as an individual, not as a statistic.

How Is Relapse Detected?

Sometimes relapse is symptomatic — a pain in a boney area caused by new or ongoing bone disease, for example — and sometimes relapse can only be picked up by a blood test or an imaging study done to monitor response in a patient receiving therapy or disease status in a patient who is off therapy. The tests used to monitor a patient for relapse are those used to establish a baseline at diagnosis. Repeating the baseline tests provides a means of comparison.

The table below lists the full scope of tests used to monitor therapy responses and possible relapse. Not every test on the table is appropriate for every patient. Your baseline testing, disease history, and treatment history will guide your doctor in the choice of tests that are appropriate for you.

Tests to Monitor Relapse and Response

Blood Tests
  • Routine blood counts.
  • Chemistry panel.
  • Liver function test.
  • Myeloma protein measurements (serum protein electrophoresis plus quantitative immunoglobulin).
  • Serum Free Light Chain Assays (Freelite®).
  • Serum ß2 microglobulin.
  • C-reactive protein.
  • Peripheral blood labeling index (LI).
  • Serum erythropoietin level.
Urine
  • Routine urinanalysis.
  • 24-hour urine for measurement of total protein, electrophoresis, and immunoelectrophoresis.
  • 24-hour urine for creatinine clearance if serum creatinine elevated.
Bone Evaluation
  • Skeletal survey by X-ray.
  • MRI/CT scan for special problems.
  • Whole-body FDG/PET scan if disease status unclear.
  • Bone density measurement (DEXA scan) as baseline and to assess benefit of bisphosphonates.
Bone Marrow
  • Aspiration and biopsy for diagnosis and periodic monitoring.
  • Special testing to assess prognosis looking for multiple potential karyotypic and FISH abnormalities (number of chromosomes, translocations, deletions — e.g. FISH 13q-, t[4;14], 1q21, etc.).


The International Myeloma Foundation medical and editorial content team

Comprised of leading medical researchers, hematologist, oncologists, oncology-certified nurses, medical editors, and medical journalists, our team has extensive knowledge of the multiple myeloma treatment and care landscape. Additionally, Dr. Brian G.M. Durie reviews and approves all medical content on this website.

Last Medical Review: October 10, 2019

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.